Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $55.50, for a total value of $55,500.00. Following the completion of the transaction, the senior vice president now directly owns 11,433 shares in the company, valued at $634,531.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Ionis Pharmaceuticals, Inc. (IONS) traded up $1.44 during midday trading on Friday, hitting $56.93. The stock had a trading volume of 1,149,432 shares, compared to its average volume of 1,468,307. Ionis Pharmaceuticals, Inc. has a 1-year low of $37.26 and a 1-year high of $65.51. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The company has a market cap of $7,080.00, a P/E ratio of 352.87 and a beta of 2.89.

IONS has been the topic of a number of recent analyst reports. Jefferies Group reaffirmed an “underperform” rating and issued a $18.00 target price (up from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $69.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Barclays cut their target price on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 21st. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $50.31.

Hedge funds and other institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $100,000. Parallel Advisors LLC grew its stake in Ionis Pharmaceuticals by 62.8% during the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after buying an additional 800 shares during the last quarter. Hanseatic Management Services Inc. grew its stake in Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the last quarter. Finally, WFG Advisors LP grew its stake in Ionis Pharmaceuticals by 77.2% during the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares during the last quarter. Institutional investors and hedge funds own 91.58% of the company’s stock.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/01/patrick-r-oneil-sells-1000-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.